McKesson stock holds firm as earnings power stays high
Published on 07/24/2026 at 12:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
McKesson (US58155Q1031) stock is anchored by the company’s latest reported scale, with fiscal 2025 revenue of $359.0 billion and adjusted earnings per diluted share of $32.73, both key markers for the health-care distributor’s current valuation backdrop.
Fiscal 2025 scale matters
The latest annual report also showed fiscal 2025 operating profit of $4.4 billion and adjusted operating profit of $4.8 billion, underscoring how the business converts volume into earnings.
Cash generation stayed central to the story as well: McKesson reported $6.0 billion in operating cash flow for fiscal 2025, while free cash flow reached $5.1 billion, figures that help explain why the share price continues to draw attention even without a fresh catalyst in the supplied search set.
Margins and cash flow
Adjusted operating margin for fiscal 2025 came in at 1.3%, a modest percentage that is typical for large pharmaceutical distribution but still important because even small changes move absolute profit by a large amount at McKesson’s revenue base.
That contrast is the main investment point here: revenue of $359.0 billion sits alongside relatively thin margins, so investors tend to focus on profit mix, working-capital discipline and the pace of cash conversion rather than headline sales growth alone.
McKesson fiscal 2025 figures and investor materials
The annual report frames the business around distribution scale, adjusted profit and cash flow, which remain the most useful numbers for following McKesson stock.
Business mix drives earnings
McKesson’s pharmaceutical distribution model remains the core earnings engine, and the fiscal 2025 numbers show why the market typically measures the company by earnings quality, not by sales growth alone.
For context, adjusted diluted EPS of $32.73 in fiscal 2025 implies that profit growth outpaced the low-margin nature of the business, while the $5.1 billion free-cash-flow figure signals substantial internal funding capacity.
Products and services
The company’s principal businesses include pharmaceutical distribution, specialty solutions and health-care services, which together tie the reported revenue base to recurring demand across the health-care system.
That mix matters because the earnings profile depends on both scale and execution, and the fiscal 2025 operating profit of $4.4 billion shows how efficiently McKesson turned that scale into bottom-line results.
Stock level watch
No dated live quote was supplied in the search set, so the most reliable market read in this article is the company’s fiscal 2025 operating backdrop rather than an unverified intraday price. The stock remains tied to the same basic equation: huge revenue, thin margins, and strong cash conversion.
McKesson stock facts
- Company: McKesson Corporation
- ISIN: US58155Q1031
- Ticker: NYSE: MCK
- Trading venue: NYSE
- Sector / Industry: Health Care / Health Care Distributors
- Index membership: S&P 500
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
